TSC2 and tuberous sclerosis: These findings suggest that rosuvastatin can reverse epigenetic silencing in TSC2−/meth cells, while rapamycin contributes its anti-proliferative effect in cells with complete TSC2 loss, pointing to a potential combinatorial therapeutic strategy in TSC-related tumors.